Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R | Q15722 | 12/20 | 1.00 |
| ▸ | LTB4R2 | Q9NPC1 | 5/20 | 0.72 |
| ▸ | TTR | P02766 | 1/20 | 0.47 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9150723 | 0.87 | LTB4R (0.76) | LTB4RLTB4R2ALDH1A1HPGD | |
| SCHEMBL9150895 | 0.84 | LTB4R (0.73) | LTB4RLTB4R2ALDH1A1HPGD | |
| SCHEMBL8583686 | 0.83 | LTB4R (1.00) | LTB4RLTB4R2 | |
| SCHEMBL8408704 | 0.83 | LTB4R (0.98) | LTB4RLTB4R2 | |
| SCHEMBL7458944 | 0.83 | LTB4R (0.98) | LTB4RLTB4R2 | |
| SCHEMBL9148197 | 0.82 | LTB4R (1.00) | LTB4RLTB4R2TTRALDH1A1HPGD | |
| SCHEMBL9149573 | 0.82 | LTB4R (1.00) | LTB4RLTB4R2GPR17 | |
| SCHEMBL9148299 | 0.81 | LTB4R (1.00) | LTB4RLTB4R2TTRALDH1A1HPGD | |
| SCHEMBL9148303 | 0.81 | LTB4R (1.00) | LTB4RLTB4R2TTRALDH1A1HPGD | |
| SCHEMBL13696764 | 0.81 | LTB4R (1.00) | LTB4RLTB4R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190216790-A1 | Methods for Treating Pruritis | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2019-07-18 | — | — | US | claimed |
| WO-2018071687-A1 | METHODS OF TREATING PRURITIS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-04-19 | — | — | WO | claimed |
| WO-2001034134-A2 | ONCOLYTIC COMBINATIONS FOR THE TREATMENT OF CANCER | ELI LILLY AND COMPANY (US) | 2001-05-17 | — | — | WO | claimed |
| WO-2001034133-A2 | ONCOLYTIC COMBINATIONS FOR THE TREATMENT OF CANCER | ELI LILLY AND COMPANY (US) | 2001-05-17 | — | — | WO | claimed |
| EP-0442748-B1 | Improvements in and relating to leukotriene antagonists | LILLY CO ELI (US) | 1995-01-11 | — | — | EP | claimed |
| EP-0442748-A1 | Improvements in and relating to leukotriene antagonists | ELI LILLY AND COMPANY (US) | 1991-08-21 | — | — | EP | claimed |
| US-4996230-A | Antiallergens, antiinflammatory agent | ELI LILLY AND COMPANY (US) | 1991-02-26 | — | — | US | claimed |
| US-20190216790-A1 | Methods for Treating Pruritis | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2019-07-18 | — | — | US | disclosed |
| WO-2018071687-A1 | METHODS OF TREATING PRURITIS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-04-19 | — | — | WO | disclosed |
| EP-0442748-B1 | Improvements in and relating to leukotriene antagonists | LILLY CO ELI (US) | 1995-01-11 | — | — | EP | disclosed |
| EP-0442748-A1 | Improvements in and relating to leukotriene antagonists | ELI LILLY AND COMPANY (US) | 1991-08-21 | — | — | EP | disclosed |
| US-4996230-A | Antiallergens, antiinflammatory agent | ELI LILLY AND COMPANY (US) | 1991-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190216790-A1 | Methods for Treating Pruritis | ITCH, CYSLTR2, CYSLTR1 | LTB4R 8/4885LTB4R2 4/4885TTR 3389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.